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ABSTRACT 24 
Lifelong exercise is associated with regulation of skeletal mass and function, reductions in 25 
frailty, and successful ageing. Yet, the influence of exercise on myostatin and myostatin-26 
interacting factors is relatively under examined in older males. Therefore, we investigated 27 
whether serum total myostatin, free myostatin, follistatin, and growth and differentiation 28 
factor 11 (GDF11) were altered following high intensity interval training (HIIT) in a group of 29 
13 lifelong sedentary (SED; 64 [6] years) and 11 lifelong exercising (LEX; 62 [6] years) 30 
older males. SED follistatin was moderately greater than LEX pre-HIIT (Cohen’s d = 0.66), 31 
and was largely greater post-HIIT (Cohen’s d = 1.22). The HIIT-induced increase in 32 
follistatin was large in SED (Cohen’s d = 0.82) and absent in LEX (Cohen’s d = 0.03). 33 
GDF11 was higher in LEX pre- (Cohen’s d = 0.49), and post- (Cohen’s d = 0.63) HIIT 34 
compared to SED. HIIT resulted in no change to GDF11 in LEX or SED (Cohen’s d = 0.00-35 
0.03). Peak power output and GDF11 correlated (r = 0.603), independent of grouping. 36 
Differences in GDF11 with lifelong exercise training, paired with the correlation between 37 
GDF11 and peak power output, suggest GDF11 may be a relevant myostatin-interacting 38 
peptide to successful ageing in humans, and strategies to maintain this need to be further 39 
explored.  40 
 41 
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INTRODUCTION 49 
Myostatin (originally growth and differentiation factor 8 [GDF8]) is a pro-catabolic, anti-50 
anabolic peptide hormone that is a central regulator of skeletal muscle mass (Elliott et al., 51 
2012). Secreted by skeletal muscle, myostatin is found in an active unbound (free) form, or 52 
bound to its own pro-peptide, or separate peptides such as follistatin, or follistatin-related 53 
gene (FLRG; Amthor et al., 2004, Gilson et al., 2009, Hill et al., 2002), each inhibiting its 54 
biological function. Myostatin has both paracrine and endocrine effects (Zimmers et al., 55 
2002), although it is the endocrine function which appears key for regulation of muscle mass, 56 
due to an observed inverse correlation with muscle mass in humans (Gonzalez-Cadavid et al., 57 
1998). Moreover, inhibition of this endocrine function results in muscle hypertrophy in mice 58 
(Whittemore et al., 2003).  59 
 60 
Ageing is associated with a progressive loss of muscle mass and associated function (Metter 61 
et al., 2002) The rate of loss of muscle mass and function with ageing is noted to differ 62 
between individuals, which gave rise to  ‘usual’ and ‘successful’ ageing hypothesis (Rowe 63 
and Kahn, 1987). A more recent definition of successful ageing being “optimisation of life 64 
expectancy while minimising physical and mental deterioration and disability” (Bowling and 65 
Dieppe, 2005), a trait that is often seen in life-long masters athletes (Pollock et al., 2015).  66 
Whilst the role of myostatin in regulation of muscle mass is well described, there are few 67 
data, and no prospective studies to contextualise the influence of myostatin within the ‘cycle 68 
of frailty’ that precedes sarcopenia. From the few cross-sectional studies, one observed ~50% 69 
higher plasma myostatin in older sedentary (~63-75 years of age) compared with younger 70 
healthy (~20-35 years of age) men (Yarasheski et al., 2002). However, this was not replicated 71 
in a study of men aged ~22, ~69, and ~76 years of age, regardless of sarcopenic severity 72 
(Ratkevicius et al., 2011). Recently, we have observed an inverse association between age 73 
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and plasma myostatin in a large group (n = 88) of healthy individuals aged 18-72 years of age 74 
(Elliott et al., 2016). Considering the current incomplete understanding concerning the role of 75 
myostatin and myostatin-interacting peptides in the ageing process, the pool of evidence 76 
needs to be extended.   77 
 78 
Growth and differentiation factor 11 (GDF11) is a peptide with similar sequence homology 79 
as myostatin, and it is possible that both peptides share similar signalling pathways and 80 
biological influence within skeletal muscle. Unlike myostatin however, the expression of 81 
GDF11 is not limited to skeletal muscle tissue (Lee and McPherron, 1999, Walker et al., 82 
2016). There also appears to be an indicated role for GDF11 in the ageing process; higher 83 
circulating GDF11 in middle-aged mice has been positively associated with longevity and 84 
exposure of aged mice to a youthful systemic environment led to restoration of skeletal 85 
muscle and hepatic cellular function (Zhou et al., 2016).  Similarly, the ageing muscle 86 
phenotype is partially offset by provision of recombinant GDF11, as demonstrated by 87 
increased grip strength and running endurance in mice (Sinha et al., 2014). 88 
 89 
Whilst it remains to be seen whether these findings can be consistently replicated, or indeed 90 
translated to the human model of ageing, only a small number of studies that have examined 91 
the effects of exercise training on serum myostatin and associated mRNA expression, whilst 92 
GDF11 remains unexamined in the human exercise model. Indeed, 2–3 months’ resistance 93 
training in healthy young individuals resulted in increased muscle mass and decreased muscle 94 
mRNA and serum myostatin (Roth et al., 2003, Walker et al., 2004). To the best of these 95 
authors’ knowledge, no reports on the effect of exercise (in any form) on GDF11 expression 96 
currently exists.  97 
 98 
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Recently, high intensity interval training (HIIT) has received much attention due to its 99 
physiological and sociological benefits. Indeed, HIIT is noted to be more enjoyable than 100 
traditional, continuous training (Thum et al., 2017), has higher compliance in patient 101 
populations than continuous training (Shiraev and Barclay, 2012), and is noted to have equal 102 
or improved clinical outcomes in a number of ageing-related cardiovascular or metabolic 103 
disorders (Cassidy et al., 2016, Ramos et al., 2015). Whilst not optimized for muscle 104 
hypertrophy, HIIT improves myofibrillar protein synthesis (Bell et al., 2015), muscle power 105 
(Sculthorpe et al., 2017), and fat free mass (FFM) (Herbert et al., 2017) in older males. 106 
 107 
Therefore, in order to progress our understanding of the biological relationship between 108 
myostatin and myostatin-interacting peptides with ageing and exercise, the aim of this 109 
preliminary study was twofold: 1) To compare resting levels of plasma myostatin and 110 
myostatin-interacting peptides between lifelong sedentary (SED) and a positive control group 111 
of lifelong exercising (LEX) ageing men, and 2) to examine the influence of 6 weeks’ HIIT 112 
on plasma myostatin and myostatin-interacting peptides in SED and LEX. We hypothesised 113 
that, on enrolment to the study, SED would exhibit higher myostatin, follistatin, free 114 
myostatin, and lower GDF11. We further hypothesized that 6 weeks’ HIIT would decrease 115 
plasma myostatin, follistatin, and free myostatin in SED, and increase GDF11.  116 
  117 
118 
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METHODS 119 
Participants 120 
Participants provided written informed consent prior to enrolment to a larger study (Hayes et 121 
al., 2017, Herbert et al., 2017, Knowles et al., 2015) which was approved by the University of 122 
the West of Scotland Ethics Committee (Reference: UEC16_042012/Herbert). Participants 123 
were familiarised with experimental procedures and approval to exercise was given by their 124 
general practitioner. Subsequently, a subgroup of 24 males were analysed for this pilot 125 
investigation. Thirteen males participated in the SED group, whilst 11 males participated in 126 
the LEX group (Table 1). Participants in the SED group did not participate in any formal 127 
exercise training and had not done so for >30 years. The LEX group were active exercisers 128 
and had been so for the previous >30 years. They consisted primarily of current masters 129 
competitors in sports including water-polo, triathlon, sprint cycling, road cycling and distance 130 
running. For six weeks prior to commencing HIIT training, LEX recorded their normal 131 
weekly exercise, which included type, frequency, intensity (recorded by heart rate telemetry), 132 
and duration of training. Time spent in low to medium intensity (<65% heart rate reserve 133 
[HRR]), and high-intensity (>65% HRR) training totalled 214 ± 131 min·wk-1 and 67 ± 52 134 
min·wk-1 respectively. Group selection was affirmed by differences in aerobic conditioning 135 
(peak oxygen uptake; VO2peak) between groups (table 1). Participants were tested pre- and 136 
post-HIIT at the same time of day, seven weeks apart. Order of measurements was blood 137 
sampling, body composition, peak power assessment, and determination of VO2peak.  138 
 139 
Table 1 about here 140 
 141 
 142 
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Blood draws and analysis 143 
Participants arrived at the exercise physiology laboratory between 07.00–09.00 h, following 144 
an overnight fast and having abstained from strenuous exercise for a minimum of 48 h. 145 
Participants were reminded to maintain standardized conditions prior to each assessment 146 
point which included arriving in a hydrated state having abstained from caffeine and alcohol 147 
consumption for 36 h. Following 20 min supine rest blood was sampled from the 148 
nondominant arm using the standard venepuncture method into sterile serum separator 149 
vacutainer tubes (Becton Dickinson, Rutherford, NJ) that were kept at room temperature in 150 
the dark, for 30 min, to allow for clotting, after which samples were centrifuged at 1100 g at 151 
4°C for 15 min. Serum was then extracted, aliquoted, and stored at −80°C until subsequent 152 
analysis. Blood samples were collected at the same time of day for each participant to control 153 
for biological variation and minimise inter-participant analytical variation. 154 
 155 
Concentrations of serum myostatin protein (both total and free fractions) were quantified by 156 
ELISA (DGDF80, R&D Systems, UK). Briefly, aliquots of serum were brought to room 157 
temperature, before 100 µL of plasma was diluted with 1:4 diluent buffer (free myostatin) or 158 
activated with 50 µL HCl (6 mol, 10 minutes at room temperature) for removal of myostatin 159 
binding proteins, before neutralization (50 µL of NaOH 6 mol + 1.2 mol HEPES) and 160 
dilution with provided diluent buffer (200 µL) to produce a final 1:4 dilution. Recombinant 161 
myostatin was used as a standard (33.3-2,000 pg·mL-1). Concentrations of serum follistatin 162 
(DFN00, R&D Systems, UK) and serum GDF11 (DY1958, R&D Systems, UK) were 163 
quantified by ELISA, per manufacturer’s instructions. Recombinant follistatin (250-16,000 164 
pg·mL-1) and GDF11 (15.6 – 1000 pg·mL-1) was used as a standard. Plates were read 165 
spectrophotometrically at 450 nm and blanked to 570 nm (VersaMax, Molecular Devices, 166 
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USA). Coefficient of variability of standards and samples were 7% and 6%, 6% and 4%, and 167 
4% and 8%, for myostatin follistatin, and GDF11, respectively.  168 
 169 
Body composition and performance measures 170 
Height was measured to the nearest 0.1 cm using a stadiometer (Seca, Birmingham, UK), and 171 
a multi frequency bioelectrical impedance analyzer (BIA; Tanita MC-180MA Body 172 
Composition Analyzer, Tanita UK Ltd.) was used to determine body mass and body 173 
composition as described elsewhere (Hayes et al., 2013b). Participant peak power output was 174 
assessed using the Herbert 6 s cycle test (Herbert et al., 2015b) and participants’ individual 175 
values were used to calculate the resistance (40% peak power output) during HIIT. VO2peak 176 
was determined by indirect calorimetry as previously described (Knowles et al., 2015). 177 
 178 
Exercise training 179 
HIIT sessions were performed once every five days, for six weeks (nine sessions in total) as 180 
previously described (Hayes et al., 2017, Herbert et al., 2017, Knowles et al., 2015). 181 
Rationale for this programme is provided by our previous work which identified that five 182 
days of recovery was required for recovery of peak power output in ageing men (Herbert et 183 
al., 2015a). Each session consisted of 6 x 30 s sprints at 40% predefined peak power output 184 
interspersed with 3 min active recovery on a cycle ergometer (Wattbike Ltd., Nottingham, 185 
UK). Sessions were conducted in groups of between four and six participants and were the 186 
sole exercise performed by both groups during this time. 187 
 188 
Statistical Analysis 189 
Following confirmation of parametricity by a Shapiro-Wilk test of normality and Levene’s 190 
test for homogeneity of variance, a mixed (between group [SED, LEX] x within individual 191 
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time [pre-HIIT, post-HIIT]) repeated measures analysis of variance (ANOVA) was used for 192 
differences in groups and time points with Bonferroni post-hoc. Non-parametric data were 193 
examined by Fishers exact test, with correction for multiple comparisons by Bonferroni’s 194 
method. Alpha level was set a priori at p < 0.05, and effect size for paired comparisons is 195 
reported as Cohen’s d throughout, interpreted as trivial (<0.2), small (≥0.2), moderate (≥0.5), 196 
and large (≥0.8). Parametric data sets are summarized in text as mean [SD], whilst non-197 
parametric are given as median (upper - lower quartile). Figures are presented as grouped dot 198 
plots, as recommended by Drummond and Vowler (2012).  199 
 200 
RESULTS 201 
Pre-HIIT, SED individuals were heavier (p = 0.131, Cohen’s d = 0.66) with a greater body fat 202 
percentage (p = 0.120, Cohen’s d = 0.66) than LEX. SED had a lower VO2peak (p < 0.001, 203 
Cohen’s d = 2.00), absolute peak power output (p = 0.036, Cohen’s d = 0.90) and relative 204 
peak power output (a surrogate for muscle quality; p = 0.020, Cohen’s d = 1.08) than LEX 205 
(table 1). 206 
 207 
There was no group x time interaction for total myostatin protein (p = 0.750), nor was there 208 
an effect of group (p = 0.081) or time (p = 0.701). However, large effect sizes were noted 209 
between SED and LEX total myostatin both pre-HITT (4217 [317] pg·mL-1 and 3394 [391] 210 
pg·mL-1 in SED and LEX respectively; Cohen’s d = 2.06; Figure 1A) and post-HIIT (4163 211 
[337] pg·mL-1 and 3678 [438] pg·mL-1 in SED and LEX respectively; Cohen’s d = 1.24). 212 
Following HIIT, SED experienced only trivial increases in total myostatin (Cohen’s d = 0.17) 213 
whilst LEX moderately increased total myostatin (Cohen’s d = 0.68). 214 
 215 
 216 
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In a similar manner to total myostatin, there was no group x time interaction for free 217 
myostatin protein (p = 0.790), nor and effect of group (0.996) or time (p = 0.601). No notable 218 
effect size changes were observed for free myostatin pre-HIIT (1182.0 [372.2] pg·mL-1 and 219 
1159.3 [418.1] pg·mL-1 in SED and LEX respectively; Cohen’s d = 0.06; Figure 1B) or post-220 
HITT (1203.3 [533.3] pg·mL-1 and 1224.5 [404.1] pg·mL-1 in SED and LEX respectively; 221 
Cohen’s d = 0.05). Moreover, neither SED (Cohen’s d = 0.05) nor LEX (Cohen’s d = 0.16) 222 
had any more than a trivial effect on free myostatin from pre- to post-HIIT. 223 
 224 
 225 
There was a significant main effect of group (p = 0.002), but not time (p = 0.171), or a group 226 
x time interaction (p = 0.561) for serum follistatin. SED follistatin was greater than LEX 227 
follistatin pre-HIIT (2508 [628] pg·mL-1 and 2102 [598] pg·mL-1 in SED and LEX 228 
respectively; p = 0.132, Cohen’s d = 0.66). SED follistatin was also greater than LEX 229 
follistatin post-HIIT (3043 [676] pg·mL-1 and 2126 [809] pg·mL-1 in SED and LEX 230 
respectively; p < 0.001, Cohen’s d = 1.22). The HIIT-induced increase in follistatin was large 231 
in SED (p = 0.011, Cohen’s d = 0.82), whilst LEX experienced no change (p = 0.443, 232 
Cohen’s d = 0.03). 233 
 234 
GDF11 data were examined by Fishers exact test, and presented as median (upper - lower 235 
quartile). GDF11 was higher in LEX pre- (p = 0.012, Cohen’s d = 0.49), and post- (p = 0.009, 236 
Cohen’s d = 0.63) HIIT compared to SED. HIIT resulted in no change to GDF11 in SED 237 
(70.7 [52.6 – 193.1], 77.1 [73.1 – 104.3] pg·mL-1 pre- and post-HIIT respectively; p = 0.74, 238 
Cohen’s d = 0.03) or LEX (272.7 [219.2 – 387.2], 305.0 [243.8 – 399.4] pg·mL-1 pre- and 239 
post-HIIT respectively; p = 0.72, Cohen’s d = 0.00). 240 
 241 
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 242 
Figure 1 about here 243 
 244 
 245 
As we have previously reported in a larger cohort (Hayes et al., 2013a), peak power output 246 
was higher in LEX individuals relative to SED (p = 0.036, Figure 2A). There was no 247 
correlation between peak power output and total myostatin (p = 0.196, r = -0.273), free 248 
myostatin (p = 0.812, r = 0.051), or follistatin (p = 0.569, r = -0.113). However, strong 249 
positive correlations were observed between GDF11 and both absolute peak power output (p 250 
= 0.002, r = 0.603; Figure 2B) and relative peak power output (p < 0.001, r = 0.636; figure 251 
2C). 252 
 253 
 254 
Figure 2 about here 255 
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 256 
DISCUSSION 257 
The main finding of this preliminary study was that SED presented greater concentrations of 258 
serum total myostatin and follistatin, and lower concentrations of GDF11, compared with 259 
LEX pre-HIIT. Serum follistatin alone responded significantly to HIIT but was confined to 260 
the SED group. A notable and novel finding from this study is the observed association 261 
between peak power output and GDF11, which has not been previously demonstrated in the 262 
human. These data provide preliminary evidence that the role of GDF11 in healthy ageing 263 
observed in mice is maintained in humans.  264 
 265 
With regards to healthy ageing, our finding that LEX displayed significantly higher GDF11 266 
than SED at baseline is novel and noteworthy. It has been noted that older mice treated with 267 
plasma from younger mice show a younger phenotype (Horrington et al., 1960, Lunsford et 268 
al., 1963), which has since been partially attributed to GDF11 differences in older and 269 
younger mice. In mice, mid-life GDF11 is predictive of longevity (Zhou et al., 2016). Aged 270 
mice show a typical ‘older muscle’ phenotype which results in lower muscle volume, 271 
endurance, and grip strength relative to young mice. Moreover, treatment with recombinant 272 
GDF11 returned grip strength to near young levels, and improved running endurance 273 
performance (Sinha et al., 2014). However, it has also been noted that GDF11 may inhibit 274 
myoblast differentiation into mature myotubes in a myostatin-like manner (Egerman et al., 275 
2015), perhaps unsurprising, as the myostatin and GDF11 peptide share ~90% homogeneity. 276 
It should be further noted that Egerman et al. (2015) used in vitro doses of 10-100 ng·mL-1, 277 
whilst both their data, and our data reported here, suggests circulating GDF11 in older males 278 
is 100-1000 pg·mL-1, an order of magnitude lower in concentration, possibly explaining the 279 
disparity of these findings.  280 
 13 
 
 281 
This argument that GDF11 concentration play a role in successful ageing is supported by two 282 
separate findings we report here. Firstly, we note GDF11 is significantly higher in LEX than 283 
SED, with some overlap between these groups. Further, we note a significant moderate 284 
positive correlation between peak power output (both absolute power and relative to FFM) 285 
and GDF11, independent of grouping. Whilst our data does not allow us to suggest causality, 286 
it is exciting to note this correlative relationship. To the best of our knowledge, this is the first 287 
dataset linking successful ageing and improved muscle function in the human with GDF11, 288 
and directly links our findings with those of Sinha et al. (2014), that exogenous GDF11 289 
protects older mice against ageing- and sedentarism-associated frailty. It is thus tempting to 290 
suggest GDF11 plays a similar role in ageing humans, and this hypothesis needs to be further 291 
explored with experimental approaches to increase GDF11 expression in humans.  292 
 293 
Circulating myostatin is noted to correlate with lean muscle mass across both healthy and 294 
cachexic individuals (Gonzalez-Cadavid et al., 1998). As SED and LEX presented with 295 
different body composition at baseline, the moderately lower concentrations of total 296 
myostatin in LEX at baseline is understandable. Whilst others have reported decreases in 297 
plasma myostatin and gains in muscle mass following resistance exercise (Walker et al., 298 
2004, Saremi et al., 2010), limited research regarding interaction between HIIT and myostatin 299 
exists. Pugh et al. (2015) reported reduced muscular myostatin mRNA in healthy individuals 300 
2 and 6 hours following a single bout of HIIT (although a different protocol to that employed 301 
herein), yet we are the first group to report chronic changes to resting serum myostatin 302 
following HIIT. The aim of HIIT is not primarily to build muscle mass, so whilst our HIIT 303 
protocol did not significantly alter serum total or free myostatin, expectations of an alteration 304 
in this peptide may have been ambitious in the absence of muscle mass alteration. 305 
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 306 
Whilst our findings concerning GDF11 are noteworthy, we acknowledge certain limitations 307 
of the present investigation. Whilst we attribute differences in GDF11 to life-long activity 308 
differences, we acknowledge that we cannot separate how much exercise was required to 309 
produce these observed differences.  The addition of a moderately active group (meeting 310 
physical activity guidelines), would allow for comparison of multiple exercise habits, rather 311 
than the two extremes presented here. Moreover, our lack of inactive control group (no HIIT) 312 
and relatively small sample size may limit interpretations. The present investigation formed 313 
part of a larger research study with other primary outcome variables (Grace et al., 2015, 314 
Herbert et al., 2017, Knowles et al., 2015), and therefore only a subset of participants were 315 
analysed. As such, our results remain preliminary until the influence of exercise habits on 316 
serum GDF11 is investigated with either a large-scale randomized control trial (RCT) or 317 
prospective observational trial.  318 
 319 
To date, much attention has been placed on myostatin itself, with alterations in myostatin 320 
expression resulting in significant and striking alterations in muscle mass in animal models 321 
(Kambadur et al., 1997, Mosher et al., 2007). However, here we show that total myostatin 322 
only moderately differs in a model of successful ageing, suggesting the role of myostatin may 323 
not be as important in successful ageing as other factors reported here. Instead, greater focus 324 
may need to be placed on these myostatin-interacting factors, as we showed follistatin was 325 
lower, and GDF11 was higher in our LEX model of successful ageing. Further, the 326 
correlation between GDF11 and muscle quality is exciting, and may suggest a protective role 327 
of GDF11 against ageing-associated muscular frailty in the human.  328 
329 
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MANUSCRIPT TABLES 487 
Table 1: Participant anthropometric and performance parameters on enrolment to the 488 
investigation in lifelong sedentary (SED), and lifelong exercising (LEX), older males. Data 489 
presented as mean [SD]. 490 
 SED (n=13) LEX (n=11) 
Age (years) 64 [6] 62 [6] 
Stature (cm) 174 [6] 174 [6] 
Body mass (kg) 91 [19] 80 [12] 
Body fat (%) 24 [16] 16 [6] 
FFM (kg) 66 [6] 66 [7] 
Peak oxygen uptake (ml·kg·min-1) 28 [6] 40 [7]* 
Peak power output (W) 663 [147] 831 [221]* 
Peak power output (W·kg FFM-1) 10 [2] 12 [2]* 
*Denotes significantly different than SED (p < 0.05). FFM = fat free mass 491 
 492 
